ToleraCyte is a pharmacologically programmed CD34+ cell therapy with potent immuno-regulatory properties being developed for the treatment of autoimmune and inflammatory diseases. Through our knowledge of CD34+ cell trafficking and the application of our cell programming expertise, we identified a small molecule combination that significantly upregulates the chemokine receptor CXCR4 on CD34+ cells and enhances the cells’ ability to traffic to sites of inflammation. Additionally, these programmed CD34+ cells have the potential to express powerful T-cell regulatory factors, including PD‐L1 and IDO1. We are investigating the potential of programmed CD34+ cells to preferentially traffic to and immunologically check autoreactive T cells, which are directly responsible for the destruction of healthy tissue in certain autoimmune and inflammatory disorders.
We have also generated immuno-regulatory hematopoietic cells from master iPSC lines that are highly enriched for myeloid markers and are free of granulocytes, erythrocytes and lymphoid cells. In in vitro assays, we have shown that these iPSC-derived immuno-regulatory cells are potent suppressors of T-cell proliferation and cytolytic activity. We are currently assessing the potential of these cells to serve as an off-the-shelf cell therapy product for the treatment of autoimmune and inflammatory diseases.